Overview

Meropenem Dosage Strategy Based on PPK Model

Status:
Completed

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

To evaluate the clinical and economical benefits of a meropenem dosage strategy based on a population pharmacokinetic(PPK)-pharmacodynamic(PD) model in lower respiratory tract infection patients.

Phase:

Phase 4

Details

Lead Sponsor:

Qingtao Zhou

Treatments:

Meropenem
Thienamycins